Liberto Erin 4
4 · Avita Therapeutics, Inc. · Filed Sep 11, 2020
Insider Transaction Report
Form 4
Liberto Erin
Chief Commercial Officer
Transactions
- Award
Stock Options (Right to Buy)
2020-09-09+6,000→ 24,000 totalExercise: $5.03From: 2020-09-09Exp: 2027-09-06→ Common Stock (6,000 underlying)
Footnotes (3)
- [F1]These Stock Options were originally exercisable for ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020 (the "Scheme"), the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable.
- [F2]The exercise price was converted from A$6.3, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (September 6, 2017). The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise.
- [F3]On September 9, 2020, the performance-based vesting condition with respect to these 6,000 Stock Options was satisfied.